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Abstract
The aim of this study was to present the contribu-
tions of the systematic review of economic evalu-
ations to the development of a national study on 
childhood hepatitis A vaccination. A literature 
review was performed in EMBASE, MEDLINE, 
WOPEC, HealthSTAR, SciELO and LILACS from 
1995 to 2010. Most of the studies (8 of 10) showed 
favorable cost-effectiveness results. Sensitivity 
analysis indicated that the most important pa-
rameters for the results were cost of the vaccine, 
hepatitis A incidence, and medical costs of the 
disease. Variability was observed in methodologi-
cal characteristics and estimates of key variables 
among the 10 studies reviewed. It is not possible 
to generalize results or transfer epidemiological 
estimates of resource utilization and costs asso-
ciated with hepatitis A to the local context. Sys-
tematic review of economic evaluation studies of 
hepatitis A vaccine demonstrated the need for a 
national analysis and provided input for the de-
velopment of a new decision-making model for 
Brazil.
Cost-Effectiveness Evaluation; Cost-Benefit Anal-
ysis; Hepatitis A; Immunization Programs
Introduction
In health systems with an ever-increasing de-
mand and limited resources, economic evalua-
tion studies have become an important tool for 
policy decisions on the incorporation of new 
health technologies.
Systematic reviews of economic studies have 
become an essential part of technological evalu-
ation and public policymaking processes. Some 
national agencies for the appraisal of health tech-
nologies [like the National Institute for Health 
and Clinical Excellence (NICE), Pharmaceutical 
Benefits Advisory Committee (PBAC), and Ca-
nadian Agency for Drugs and Technologies in 
Health (CADTH)] require systematic review of 
the relevant economic literature for evaluation 
and policymaking processes in public health 1.
The methodology for summarizing the re-
sults of economic evaluations is not as well-
developed as that applied to clinical evidence. 
The most solidly established methods for sum-
marizing economic evaluations are: narratives 
summary, the cost-effectiveness plane, and per-
mutation matrices 2.
The summary should begin with descriptive 
comparisons of the study questions, methods, 
and results. It can be useful to include tables that 
summarize the key information on the popula-
tion, country, study perspective, comparison of 
interventions, outcomes, summary measures, 
and incremental cost-effectiveness ratios 3. The-
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oretically, a meta-analysis of economic evalua-
tions can be performed, but in practice it is not 
a simple procedure 4. The lack of details in esti-
mates, variability in the outcomes used for ef-
fectiveness, and heterogeneity of the economic 
evaluations identified in the literature hinder 
a meta-analysis of the results 3. In most cases, 
statistical “pooling” of the cost-effectiveness es-
timates (meta-analysis) is neither feasible, nor 
does it make sense 1. Narrative synthesis has 
been the most widely used method.
The systematic review of economic studies 
has been indicated to: (1) contribute to the devel-
opment of a new decision model; (2) identify one 
or two more relevant studies to inform a particu-
lar decision in a jurisdiction; or (3) identify the 
principal economic “trade-offs” in a given treat-
ment choice or disease area 1.
In Brazil, the National Immunization Pro-
gram (PNI) commissioned an economic study 
to estimate the cost-effectiveness of incorporat-
ing the hepatitis A vaccine. The hepatitis A vac-
cine has been commercially available since the 
early 1990s 5 and has proven safe and effective. 
In Israel, universal childhood vaccination has 
been conducted with great success since 1999 6,7.
Argentina in 2005 8 and the United States in 
2006 9 also implemented programs for universal 
childhood vaccination against hepatitis A, with 
a major impact on the epidemiology of the dis-
ease 10. The pattern of hepatitis A endemicity in 
Brazil suggests that the introduction of a uni-
versal childhood vaccination program would be 
beneficial.
In this context, a systematic review of previ-
ous economic evaluations is necessary in order 
to verify whether a recent analysis has been per-
formed in Brazil, with similar objectives. Two sys-
tematic reviews on the hepatitis A vaccine were 
published recently, approaching methodological 
issues related to the use of economic evaluation 
models 11 and the methodological quality of eco-
nomic evaluations of various vaccines 12.
A systematic review is thus necessary that 
includes complete economic evaluation studies 
analyzing the use of the hepatitis A vaccine in 
a program for universal vaccination of children 
up to six years of age. This cutoff was set for the 
current study considering the most adequate age 
for vaccination in Brazil, based on the epidemio-
logical pattern of hepatitis A in transition, with 
regional variation, including areas of intermedi-
ate and low endemicity 13,14.
When a new economic evaluation is justified, 
a review of previous economic studies can pro-
vide input for the development of a new decision 
model. This type of review is useful for compar-
ing and contrasting how different researchers 
made their choices in relation to the methodol-
ogy and the estimation of key variables and to 
clarify how the results of analyses can differ ac-
cording to these choices 15.
A systematic review of the existing economic 
studies allows evaluating whether the results can 
be generalizable or transferable and establishes 
the need (or lack thereof) for developing local 
studies to estimate the cost-effectiveness ratio of 
the new vaccine to be incorporated.
The aim of this study is to present the con-
tributions of a systematic review of economic 
evaluations to the development of a Brazilian na-
tional study, based on the example of childhood 
hepatitis A vaccination. The article discusses the 
importance of this review and its applicability to 
the design of a local economic evaluation and the 
definition of public policies for immunization in 
the country.
Methods
Literature search
On May 26, 2010, a search was conducted in six 
databases: EMBASE, MEDLINE, WOPEC, Health-
STAR, SciELO, and LILACS. The strategy (“eco-
nomic evaluation” OR “cost” OR “cost-benefit” 
OR “cost-effectiveness” OR “cost-utility” OR “de-
cision analysis”) AND (“hepatitis A” OR “hepatitis 
A vaccines”) was used in all the databases and 
was limited to articles published from 1995 to 
May 2010. On December 30, 2010, a new search 
was conducted, and no new publications were 
identified.
Inclusion/exclusion criteria
The following selection criteria were used:
• Study design: complete economic evaluation, 
defined as a comparative analysis of costs and 
consequences of two alternative healthcare in-
terventions; including cost-minimization analy-
sis, cost-effectiveness analysis, cost-utility analy-
sis, and cost-benefit analysis;
• Type of intervention: universal childhood 
hepatitis A immunization program;
• Population: children up to 6 years of age.
The review excluded incomplete economic 
evaluations, like cost analyses, and economic 
evaluations of specific groups such as workers, 
travelers, prison inmates, university students, 
adolescents, hepatitis C patients, and others.
The review also excluded studies that ana-
lyzed the combined hepatitis A+B vaccine, since 
this vaccine, like the hepatitis A vaccine, is rec-
ommended for use starting at 12 months, and 
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hepatitis B vaccination is recommended soon af-
ter birth (1st dose administered in the maternity 
ward) 16 and is already included as routine in the 
Brazilian National Immunization Program.
Each study was reviewed in detail to extract 
and summarize information on:
• Methodological characteristics: type of study, 
perspective, model, herd protection, time ho-
rizon, number of cohorts, currency and year of 
costs, discount rate, sensitivity analysis, and pa-
rameters are varied in the sensitivity analysis;
• Estimates of key variables: epidemiological 
(incidence, symptomatic outcomes, and case-
fatality rate); characteristics of the vaccine (vac-
cination scheme, coverage, efficacy, adverse 
events, and annual rate of waning of protec-
tion); costs (direct and indirect), and summary 
measures.
To compare the results of the studies, the 
summary measures or incremental cost-effec-
tiveness ratios (ICERs) were converted into U.S. 
dollars (US$) for 2005 using purchasing power 
parity (PPP), which is the exchange-rate equiva-
lent of an identical basket of goods and services 
in two countries 17. The monetary values of the 
results were corrected by the consumer price in-
dex for all annual urban consumers of healthcare 
in 2005 18. Whenever the study did not specify the 
year of cost, it was assumed that the year of cost 
was the same as that of the study’s publication. 
This strategy had been adopted previously in the 
literature 12.
In addition, the research funding sources 
were identified in order to assess whether they 
influenced the studies’ results.
The methodology used for summarizing eco-
nomic evaluation studies was narrative synthesis. 
The methodological characteristics and estimates 
of key variables are shown in summary tables.
Results
Literature review 
The initial searches identified approximately 
1,047 articles. After reading the titles and/or ab-
stracts, 20 studies were considered potentially rel-
evant and retrieved in full text. At this stage, only 
one Brazilian article was selected, from the State 
of Paraná 19. However, after reading the complete 
article it was excluded, since it turned out to be 
a cost analysis, or incomplete economic evalu-
ation. The authors compared the costs of two 
strategies: not vaccinating and vaccinating. The 
non-vaccination strategy included direct medi-
cal costs with consultations, laboratory tests, se-
rological diagnostic tests (IgM), fulminant hepa-
titis, transplants, and retransplantation. The vac-
cination strategy included the costs of vaccine 
doses and medical consultations due to adverse 
events. In order for the study to be considered 
a complete economic evaluation, in addition to 
costs it would have had to compare the health 
outcomes, for example hepatitis A cases averted.
After reading the full text of the 20 studies, 10 
studies met the inclusion/exclusion criteria and 
will be discussed in the current review.
Methodological characteristics of the studies
Table 1 shows the methodological characteris-
tics of the 10 studies 20,21,22,23,24,25,26,27,28,29 ana-
lyzed in the current review. Half of the studies 
were conducted in developed countries, the 
oldest 20 failed to specify the country but used 
U.S. data in its analysis, three studies were per-
formed in the United States 21,22,23, and one in 
Israel 24. Four studies were conducted in South 
America, including two in Chile 25,26 and two in 
Argentina 27,28, and one study in China 29.
As specified by the authors, four studies per-
formed cost-effectiveness analysis, three did 
cost-utility analysis, two did joint cost-effective-
ness and cost-utility analysis, and only one did 
cost-benefit analysis.
As for the perspective from which the analysis 
was performed, the 10 studies adopted society’s 
perspective, which is that recommended for vac-
cination programs planned to improve public 
health, because it considers both the direct and 
indirect costs of the intervention. Direct costs are 
those directly related to the disease and are divid-
ed into medical and non-medical. Direct medical 
costs are those immediately related to diagno-
sis, treatment, and rehabilitation. They include 
tests, medicines, clinical or surgical procedures, 
etc. Meanwhile, direct non-medical costs include 
family costs with transportation (of the patient 
and accompanying person for receiving care), 
food (changes in the patient’s normal diet), etc. 
Indirect costs are related to loss of income and/or 
productivity and disability or death of productive 
persons as a result of the disease. Importantly, 
lost productivity is not limited to the patient; 
costs related to the persons (caregivers) who miss 
work in order to care for the patient should also 
be taken into account.
In addition to society’s perspective, four 
studies 22,25,26,29 also took the perspectives of 
the healthcare system and public payer, which 
are relevant for assisting decision-making in the 
health sector.
As for the selected model, most of the stud-
ies (7 of 10) used a Markov static model 20,21,22,
23,25,28,29. Two studies used dynamic models 26,27. 
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Table 1
Methodological characteristics of economic evaluations of hepatitis A immunization programs.
Study/
Country
Type 
of study
Perspective Model Herd 
protection
Time 
horizon 
(years)
Cohorts Currency/
Year of 
Costs
Discount 
rate
Sensitivity 
rate
Parameters varied in 
the sensitivity analysis
Das 20/
Developed 
country
CUA Society Static 
(Markov)
Not included 74.5 1 ND Cost: 3%; 
Benefit: 3%
Univariate; 
Multivariate
Vaccination coverage; 
natural immunity; 
annual rate of waning of 
protection; incidence; 
case-fatality; costs; acute 
episodes of hepatitis 
a; doses of vaccine; 
serological tests; discount 
rate
Ginsberg et 
al. 24/Israel
CBA Society Proxy 
model
Included 45 ND US$/1997 Cost: 4%; 
Benefit 4%
Univariate; 
Break-even
Incidence; vaccine 
efficacy; time horizon; 
discount rate
Jacobs et 
al. 22/USA
CUA Healthcare 
system/
Society
Static 
(Markov)
ND 83 1 US$/2002 Cost: 3%; 
Benefit 3%
Univariate; 
Multivariate
Discount rate; incidence; 
annual rate of waning 
of protection; price of 
vaccine; administration 
fee; QALY of 
symptomatic infections; 
hospitalizations; 
transplants; case-fatality
Valenzuela 
et al. 25/
Chile
CEA Healthcare 
system/
Society
Static 
(Markov)
Partially 
included
50 1 US$/2004 Cost: 3%; 
Benefit 3%
Univariate Case-fatality; annual rate 
of waning of protection; 
costs; medical; doses of 
vaccine; lost workdays; 
discount rate
Rein et 
al. 23/USA
CEA Society Static 
(Markov)
Not included 95 1 US$/2005 Cost: 3%; 
Benefit 3%
Univariate; 
Multivariate; 
Probabilistic
Incidence; vaccination 
coverage in adults; 
annual rate of waning 
of protection; adverse 
events; QALYs; public 
health costs; cost of dose 
of vaccine; administration 
cost; discount rate
Armstrong 
et al. 21/USA
CEA Society Static 
(Markov)
Included 95 10 US$/2005 Cost: 3%; 
Benefit 3%
Univariate Incidence; vaccination 
coverage; annual rate 
of waning of protection; 
QALYs; cost of vaccine
Lopez et 
al. 27/
Argentina
CEA Society Dynamic 
(SIR)
Included 100 100 US$/2004 Cost: 3%; 
Benefit: ND
Univariate Annual reduction of force 
of infection; vaccination 
coverage; herd 
protection; time horizon; 
discount rate
Ellis et al. 28/
Argentina
CUA Society Static 
(Markov)
ND 50 1 US$/2005 Cost: 3%; 
Benefit: 3%
Univariate; 
Multivariate
Annual rate of waning of 
protection; cost of dose 
of vaccine
(continues)
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Table 1 (continued)
Study/
Country
Type 
of study
Perspective Model Herd 
protection
Time 
horizon 
(years)
Cohorts Currency/
Year of 
Costs
Discount 
rate
Sensitivity 
rate
Various parameters in 
the sensitivity analysis
Quezada et 
al. 26/Chile
CEA Public payer/
Society
Dynamic 
(SIR)
Included 100 100 US$/2005 Cost: 3%; 
Benefit: 3%
Univariate; 
Multivariate; 
Best and 
worst-case 
scenarios
Annual reduction of 
force of infection; 
vaccination coverage; 
herd protection; costs 
of disease; time horizon; 
discount rate
Zhuang et 
al. 29/China
CEA; 
CUA
Healthcare 
system/
Society
Static 
(Markov)
Not included 72 1 RMB 
Yuan/2005
Cost: 5%; 
Benefit 5%
Univariate; 
Multivariate
Vaccination coverage 
(1 and 2 doses); vaccine 
efficacy; annual rate of 
waning of protection; 
incidence; proportion of 
symptomatic infections; 
duration of symptoms; 
hospitalization; case-
fatality; missed workdays; 
cost of vaccine; medical 
costs of hepatitis A; 
utility score for hepatitis 
A; annual growth in per 
capita GDP; discount rate
CBA: cost-benefi t analysis; CEA: cost-effectiveness analysis; CUA: cost-utility analysis; ND: not determined; QALY: quality-adjusted life year; GDP: gross 
domestic product; SIR: susceptible, infected, recovered.
The inclusion of herd protection in the eco-
nomic analysis can make the program more 
cost-effective, because it increases the number 
of cases averted. It was included in four studies 
21,24,26,27 and partially included in one 25. Two of 
these studies 21,25 included herd protection in 
their analysis, despite using static models. The 
study by Armstrong assumed a fixed proportion 
in the decline in infections, attributed to herd 
protection for persons within the vaccinated co-
hort and for the unvaccinated 21. In Valenzuela 
et al. 25, it was not clear how this was done. It 
should be emphasized that static models usu-
ally fail to consider indirect effects of vaccina-
tion such as herd protection and shift in the age 
at infection to older age groups. Some studies 
using static models consider herd protection, 
assuming that a fixed percentage of the unvac-
cinated population is protected by the vaccina-
tion of the vaccinated cohort 11. However, an-
other characteristic of herd protection, namely 
an increase in the age group of infection, can 
lead to an increase in the frequency of symp-
tomatic cases and consequently a change (in-
crease) in the use of health services, not consid-
ered in static models. The inclusion of only the 
positive aspects of herd protection can result 
Finally, one study was unable to develop a dy-
namic model (which the author considered the 
gold standard) and thus developed a “proxy mod-
el”, not described clearly by the author 24.
The “dynamic” model allows projecting 
changes in transmission patterns, i.e., reduction 
in the force of infection resulting from the vacci-
nation program. Universal vaccination programs 
can result in complex indirect effects known as 
“herd protection”: unvaccinated susceptible in-
dividuals are protected from the disease by the 
decrease in transmission of the pathogen, which 
can lead to a shift in the age at infection to older 
age groups. Meanwhile, a “static” model does 
not allow incorporating change into the force of 
infection over time. Although theoretically the 
dynamic models estimate changes in the epide-
miological pattern more accurately, they require 
larger amounts of data, which are not always 
available. For example, the lack of data on the 
annual decrease in the force of infection and se-
roprevalence for hepatitis A in some age groups 
lead authors to make assumptions that introduce 
uncertainties into the model. Despite the great 
methodological sophistication, the final results 
depend on the availability and quality of the data 
used to feed the model 26.
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Table 2
Epidemiological estimates used in economic evaluations.
Study Incidence Source Symptomatic outcomes Source Case-fatality rate 
(%)
Source
Das 20 Annual hepatitis 
A incidence in 
the unvaccinated 
population: 0.0001
ACIP Episodes of acute 
hepatitis
ACIP < 50 years: 0.3; 
> 50 years: 2.5
2 national articles
Ginsberg et 
al. 24
% cases of hepatitis 
type A; Reported 
cases of hepatitis A: 
54/100,000
National statistics 
and Ministry of 
Health
Mild and moderate 
cases: 84%; outpatient 
cases with relapse: 5.5%; 
inpatient cases with 
relapse: 2.7%; severe 
hospital cases: 7.6%; 
non-fatal FHF without 
transplant: 0.024%; fatal 
FHF without transplant: 
0.028%; non-fatal FHF 
with transplant: 0.062%; 
fatal FHF with transplant: 
0.008%
Personal 
communication 
and national data
0.0071 Ministry of Health
Jacobs et 
al. 22
Hepatitis A infection 
rates by age and 
region * and national 
rate
SNVEDN Symptomatic infection 
rate (≤ 4 years: 7%; 
5-9 years: 37%; 
10-17 years: 71%; 
18-29 years: 73%; 
30-39 years: 74%; 
40-49 years: 78%; 
50-59 years: 82%; 
60-69 years: 86%; 
≥ 70 years: 90%); 
hospitalization rate 
(≤ 14 years: 5%; 15-29 
years: 10%; 30-39 years: 
11%; 40-49 years: 15%; 
50-59 years: 21%; 60-69 
years: 26%; 70-79 years: 
33%; 
≥ 80 years: 43%); 
transplant rate 
(≤ 14 years: 0%; 
15-39 years: 0.02%; 
40-49 years: 0.05%; 
≥ 50 years: 0.08%)
2 national articles; 
8 national articles; 
2 national articles
Case-fatality rate 
(≤ 14 years: 0.14%; 
15-29 years: 0.18%; 
30-39 years: 0.21%; 
40-49 years: 0.36%; 
50-59 years: 0.81%; 
60-69 years: 1.49%; 
70-79 years: 2.83%; 
≥ 80 years: 3.85%)
7 national articles
Valenzuela 
et al. 25
Reported hepatitis 
A infection rates per 
100,000 (1-4 years: 
99.1; 5-9 years: 
259.7; 10-14 years: 
154.0; 15-19 years: 
55.8; 20-24 years: 
31.0; 25-34 years: 
14.7; 35-44 years: 
6.9; 45-50 years: 5.6)
Ministry of Health 
and surveillance 
data
Proportion of hepatitis 
A cases causing overt 
disease (1-4 years: 7%; 
5-9 years: 37%; 10-17 
years: 71%; 18-29 years: 
73%; 30-39 years: 74%; 
40-50 years: 78%); 
Hospitalization rate in 
overt hepatitis (0-14 years: 
8%; > 14 years: 11%)
3 national articles; 
Ministry of Health
0-14 years: 0.14%; 
15-29 years: 0.18%; 
30-39 years: 0.21%; 
40-50 years: 0.36%
1 international 
article
(continues)
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Table 2 (continued)
Study Incidence Source Symptomatic outcomes Source Case-fatality rate 
(%)
Source
Rein et al. 23 Reported annual 
hepatitis A incidence 
by age and region **
2 national articles Infection rate without 
jaundice with nonspecific 
symptoms (0.5); Infection 
rate with jaundice (0-4 
years: 0.076; 5-14 years: 
0.512; 15-95 years:0.832); 
Hospitalization rate of 
reported cases with 
jaundice (0-4 years: 0.05; 
5-14 years: 0.17; 15-39 
years: 0.23; 40-59 years: 
0.19; 60-95 years: 0.2)
Assumption; 1 
national article; 1 
national article
Case-fatality rate in 
cases with jaundice 
(0-4 years: 0.00030; 
5-14 years: 0.00004; 
15-39 years: 
0.00054; 40-59 
years: 0.00436; 60-
95 years: 0.1276)
1 national article
Armstrong 
et al. 21
Reported annual 
hepatitis A incidence 
by age and 
region ***
2 national articles Infection rate without 
jaundice with nonspecific 
symptoms (0.5); Infection 
rate with jaundice (0-4 
years: 0.076; 5-14 years: 
0.512; 15-95 years: 0.832); 
Hospitalization rate of 
reported cases with 
jaundice (0-4 years: 0.05; 
5-14 years: 0.17; 15-39 
years: 0.23; 40-59 years: 
0.19; 60-95 years: 0.2)
Assumption; 1 
national article; 1 
national article
Case-fatality rate in 
cases with jaundice 
(0-4 years: 0.00030; 
5-14 years: 0.00004; 
15-39 years: 
0.00054; 40-59 
years: 0.00436; 60-
95 years: 0.1276)
1 national article
Lopez et 
al. 27
Age-specific force of 
infection based on 
seroprevalence data
Published data in 
Latin America and 
Argentina
Risk of jaundice: 
85.2%; Risk of FHF 
per symptomatic case: 
0.00085; Risk of transplant 
per symptomatic case: 
0.00072; Risk of re-
transplantation per 
symptomatic case: 
0.00014; Risk of relapse 
per symptomatic 
case: 0.15; Risk of 
hospitalization per 
symptomatic case: 0.05
Ministry of Health 
and 1 international 
article; 2 national 
articles; 1 
international article; 
2 national articles; 1 
international article
Age-specific per 
100,000 (≤ 14 years: 
140; 15-29 years: 
180; 30-39 years: 
210; 40-49 years: 
360; 50-59 years: 
810; 60-69 years: 
1,490; 70-79 years: 
2,630; ≥ 80 years: 
3,850)
2 international 
articles
Ellis et al. 28 Reported annual 
hepatitis A incidence 
per age and region # 
and national rate
Ministry of Health; 
National statistics
Hepatitis A cases; 
Proportion of infection 
with symptoms (1-4 years: 
7%; 5-9 years: 37%; 10-
14 years: 71%; 15-49 
years: 75.7%; ≥ 50 years: 
86%); Hospitalization 
(0-14 years: 2.6%; 15-29 
years: 3.6%; 30-39 years: 
3.6%; > 39 years: 3.6%); 
Transplant (0-14 years: 
0.027%; 15-29 years: 
0.127%; 30-39 years: 
0.127%; > 39 years: 
0.127%)
Ministry of Health; 
2 international 
articles; National 
data and 1 
international article; 
1 national article; 
National statistics
0-14 years: 0.14%; 
15-29 years: 0.18%; 
30-39 years: 0.21%; 
> 39 years: 0.36%
2 international 
articles
(continues)
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Table 2 (continued)
Study Incidence Source Symptomatic outcomes Source Case-fatality rate 
(%)
Source
Quezada et 
al. 26
Age-specific force of 
infection based on 
seroprevalence data
Data published in 
Chile
Infected individuals 
with jaundice (85.2%); 
Hospitalization (0-14 
years: 0.08; ≥ 15 years: 
0.11); Transplant (0-14 
years: 0.0001; ≥ 15 years: 
0.0003)
2 international 
articles
Age-specific per 
100,000 
(≤ 14 years: 140; 
15-29 years: 180; 
30-39 years: 210; 
40-49 years: 360; 
50-59 years: 810; 
60-69 years: 1.490; 
70-79 years: 2.630; 
≥ 80 years: 3.850)
2 international 
articles; Ministry of 
Health, Argentina
Zhuang et 
al. 29
Annual incidence 
based on 
region-specific 
seroprevalence 
data ##
National technical 
document 
Proportion of infections 
with symptoms (1-4 years: 
7%; 5-9 years: 37%; 10-17 
years: 71%; ≥ 18-years: 
75%); Hospitalization 
(1-14 years: 0.08; ≥ 15 
years: 0.15)
4 international 
articles; 2 
international articles
1-4 years: 0.0030; 
15-39 years: 
0.00054; 40-59 
years: 0.00436; ≥ 60 
years: 0.1276
1 international 
article
ACIP: Advisory Committee on Immunization Practices (USA); FHF: fulminant hepatic failure; SNVEDN: National System for Epidemiological Surveillance of 
Diseases of Notifi cation.
* 4 regions: ≥ 200% of mean national incidence, 100-199% of mean national incidence, 50-99% of mean national incidence, ≤ 50% of mean national incidence;
** 3 regions: regions 1 and 2 (incidence 1-2 times the national mean), region 3 (national mean);
*** 3 regions: region with high endemicity, region with intermediate endemicity, and region with low endemicity;
# 5 regions: Northeast and Central regions (incidence below the national mean), South (national mean), Cuyo and Northwest regions (incidence above the 
national mean);
## 5 regions: very low prevalence of hepatitis antibodies A (50%), low prevalence of hepatitis A antibodies (50-69%), intermediate prevalence of hepatitis A 
antibodies (70-79%), high prevalence of hepatitis A antibodies (80-89%), very high prevalence of hepatitis A antibodies (90%).
in overestimation of the vaccination program’s 
beneficial effects.
The inclusion of herd protection can have a 
major impact on the vaccination program’s pre-
dicted outcomes. For example, Ginsberg et al. 24,
when modeling the potential economic and 
health benefits of an immunization program for 
children 1-2 years of age in Israel, estimated that 
it would take 15 years for the program to reduce 
symptomatic cases by 90%. However, in real life, 
routine immunization in Israel achieved a reduc-
tion of greater than 90% in just three years, due 
partially to the herd protection induced by vac-
cination 6.
The majority of the studies (7 of 10) used long 
time horizons, more than 70 years, accompanying 
the life expectancy of the cohorts 20,21,22,23,26,27,29. 
They all used standard discount rates, from 3 to 
5%, and only one study 27 failed to report the dis-
count of benefits.
Estimates of key variables
Epidemiological estimates• 
Table 2 summarizes the epidemiological esti-
mates used in the economic evaluations.
All the studies used local data to build esti-
mates of incidence and force of infection. Four 
studies 21,22,23,28 presented data on regional in-
cidence and conducted regional and nationwide 
cost-effectiveness analyses. The study in China 29 
conducted only regional analyses, without pre-
senting a nationwide analysis.
The most frequently used outcomes were out-
patient cases, inpatient cases, transplant cases, 
and deaths. To estimate the number of symptom-
atic cases, eight studies 21,22,23,25,26,27,28,29 used the 
study by Armstrong & Bell 30 which calculated the 
probability of developing jaundice during acute 
hepatitis A according to age group, utilizing data 
from different primary studies.
As for case-fatality, the majority of the stud-
ies used data from national studies or data fur-
nished by the Ministry of Health to construct 
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their local estimate, and only four studies in 
Argentina 27,28, Chile 26, and China 29 used U.S. 
case-fatality data.
Characteristics of the vaccine• 
Table 3 presents the vaccine’s characteristics. In 
relation to the vaccination scheme, most stud-
ies adopted vaccination of children up to 24 
months of age. Only two studies evaluated the 
strategy with a second dose at 54 and 72 months 
of age 25,28. And only one Argentine study evalu-
ated single-dose vaccination 28. Argentina is the 
only country to have implemented a single-dose 
immunization program against hepatitis A 8.
As for vaccination coverage, only three stud-
ies used more conservative coverage rates, from 
69 to 89% 20,22,29.
All the studies used data on vaccine efficacy 
(percentage risk reduction in vaccinated individ-
uals as observed in clinical trials). No study pre-
sented data on effectiveness (percentage risk re-
duction in vaccinated individuals as observed in 
routine use of the vaccine). Efficacy rates ranged 
from 91 to 98% for the first dose and from 95 to 
100% for the second dose.
Data in the literature suggest that protection 
provided by the hepatitis A vaccine is long-last-
ing: persistence of antibodies or anamnestic re-
sponse to a booster dose of the vaccine, or both, 
was demonstrated up to 12 years after the 2-dose 
vaccination scheme 31. Even so, the analyses in 
the 10 studies assumed waning of protection over 
time after vaccination. Five studies 20,21,22,23,24 
used estimates based on models of antibody per-
sistence 32,33. Three of these studies 25,28,29 used 
estimates constructed by an expert panel in the 
United States (1.62% per year in the first 10 years 
and 2.67% thereafter, after one dose of the vac-
cine, and 0.31% and 0.62% after two doses) 34. 
Two studies 26,27, despite using the same expert 
panel cited above as the reference 34 , presented 
an estimate of 0.58% per year, without specifying 
at what year after vaccination the waning of im-
munity was expected to occur.
Cost estimates• 
Table 4 summarizes the elements considered in 
the cost estimates. All the studies included di-
rect medical costs, costs with the vaccine, and 
indirect costs. In most cases, direct medical 
costs were related to treatment of hepatitis A in 
outpatients, inpatients, hepatic failure with or 
without subsequent transplant, and follow-up 
of transplant patients. All the studies used lo-
cal data to estimate direct medical costs, except 
for Quezada et al. 26, in Chile, who used inter-
national studies, and Armstrong et al. 21, who 
did not specify the sources used to construct the 
direct cost estimates. The four studies 22,23,25,28 
that included costs with follow-up of transplant 
patients used data from studies by Berge et 
al. 35 and/or Hauboldt 36, conducted in the Unit-
ed States.
As for costs with the vaccine, nine studies 
considered the values for the dose and adminis-
tration, two studies included the cost of adverse 
events 24,26 , and only one included the cost of 
wasted vaccines and transportation to receive 
the vaccine 24.
As for indirect costs, eight studies calculated 
lost productivity due to the disease for patients, 
while four studies also calculated lost productiv-
ity for caregivers. One study calculated the wage 
losses of spouses, assuming that they acted as 
caregivers 24. Four studies 20,22,23,25 only used lo-
cal data to estimate indirect costs, three 24,28,29 
used international articles, and three 21,26,27 failed 
to specify their sources. In general, the calcula-
tion was performed using the country’s median 
wage, adjusted for the unemployment rate. Only 
one study 29 used per capita GDP to construct 
this estimate, due to the lack of a reliable national 
wage estimate.
The number of lost workdays varied from 
13.25 days in mild to moderate cases up to a year 
and a half for persons with non-fatal fulminant 
hepatic failure with transplant. In hospital cases 
this figure ranged from 33 to 71 days. Referring 
to the same source 35, different authors 25,28,29,34 
reported different estimates of lost workdays.
Results of the analyses
Table 5 shows the summary measures presented 
in the results of the analyses. In general, stud-
ies funded by industry reported more favorable 
ICERs than the independent studies. All the stud-
ies showed favorable cost-effectiveness results, 
below US$ 20,000 per quality-adjusted life year 
(QALY) gained 37, except for two independent 
studies 21,23 that showed ICERs of US$ 28,000 
and US$ 32,000 per QALY gained, respectively. 
When the latter included herd protection in the 
analysis, the ICER dropped from US$ 32,000 to 
US$ 1,000 per QALY gained.
One study 20 found that the hepatitis A vac-
cine was within the accepted cost-effective 
range, using US$ 42,000 per year of life saved 
as the cutoff 38. Jacobs et al. 22 found the value 
of the hepatitis A vaccination program compa-
rable to that of other immunization programs. 
Valenzuela et al. 25 and Zhuang et al. 29 used per 
capita GDP as the cost-effectiveness parameter. 
Rein et al. 23 found the hepatitis A immunization 
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Table 3
Characteristics of vaccine.
Study Vaccination scheme Coverage (%) Efficacy (%) Adverse events 
(%)
Annual rate of waning of 
protection (%)1st dose 2nd dose 1st dose 2nd dose
Das 20 2 doses (0 and 6-12 months) 80 80 ND ND NC 12 *
Ginsberg 
et al. 24
2 doses (15 and 24 months) 95 92 94 95 Mild (1.25: 1st 
dose; 2.50: 2nd 
dose)
2 (after 10 years)
Jacobs et al. 22 2 doses (2 years) 89 69 98 99 NC 2.3 **
Valenzuela 
et al. 25
2 doses (18 and 24 months or 
18 and 54 months)
96 80 
(24 months); 
92.2 
(54 months)
98 99 ND With 1 dose: 1.62 (1-10 
years); 2.67 (after 10 years)
With 2 doses: 0.31 (1-10 
years); 0.62 (after 10 years)
Rein et al. 23 2 doses (12 months) 93 87 91 100 Mild: 0.5; 
Severe: 0.0001
20 (1-5 years); 
5 (after 5 years)
Armstrong 
et al. 21
2 doses (12 months) 93 87 91 100 Mild: 0.5; 
Severe: 0.0001
20 (1-5 years); 
5 (after 5 years)
Lopez et al. 27 2 doses (12 and 18 months) 95 95 95 100 0.03 0.58 *
Ellis et al. 28 1 dose (12 months) or 
2 doses (12 and 18 months or 
12 and 72 months)
95 76 
(18 months); 
66.5 
(72 months)
98 99 ND With 1 dose: 1.62 (1-10 
years); 2.67 (after 10 years)
With 2 doses: 0.31 (1-10 
years); 0.62 (after 10 years)
Quezada 
et al. 26
2 doses (12 and 18 months) 95 95 95 100 0.03 0.58 *
Zhuang et al. 29 2 doses (12 and 18 months) 85 80 93 95 ND With 1 dose: 1.62 (1-10 
years); 2.67 (after 10 years)
With 2 doses: 0.31 (1-10 
years); 0.62 (after 10 years)
NC: not considered; ND: Not determined.
* Not determined at what year waning of protection begins;
** Waning of protection twice as fast in individuals that received only 1 dose of vaccine.
program cost-effective, since it was comparable 
to other public health interventions such as dia-
betes screening in patients with hypertension 
(US$ 34,000) and HIV screening in the general 
population (US$ 42,000). The other five authors 
21,24,26,27,28 did not specify the cost-effectiveness 
criterion used when interpreting the results.
Universal childhood hepatitis A vaccination 
proved to be cost-saving (costs iess and is more 
effective than the non-vaccination strategy) in 
areas with higher incidence of the disease in 
Argentina 28 and the United States 22,23. In Ellis 
et al. 28, vaccination proved to be cost-saving in 
the Cuyo region (high endemicity), while in the 
South region (intermediate endemicity) the ICER 
was US$ 673 per QALY gained and in the North-
east region (low endemicity) the ICER was US$ 
2,772 per QALY gained. Jacobs et al. 22 showed 
similar findings: the vaccination program proved 
to be cost-saving in regions with incidence rates 
≥ 200% and 100-199% of the national average, 
while in regions with incidence rates 50-99% of 
the national average the ICER was US$ 13,800 per 
QALY gained and with incidence rates < 50% of 
the national average the ICER was US$ 63,000 per 
QALY gained. In Rein et al. 23, vaccination proved 
to be cost-saving in regions 1 and 2 (with twice 
the mean national incidence), and in region 3 
(with the country’s mean incidence) the ICER 
was US$ 133,000 per QALY saved.
Meanwhile, in China 29, in areas with the 
lowest, low, intermediate, and high prevalence 
of hepatitis A antibodies, the immunization pro-
gram proved to be cost-saving, but in areas with 
extremely high prevalence of hepatitis A antibod-
ies, the ICER was US$ 277.
Countries described their regional inci-
dence/prevalence rates as high, intermediate, or 
low in relation to the national average. However, 
the national average differs between countries. 
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Table 4
Elements considered in cost estimates.
Study Cost elements Sources
Das 20 Direct medical costs: acute episodes of hepatitis A 2 national articles
Costs with vaccine: dose; administration; hepatitis A antibody tests 3 national articles
Indirect costs: lost productivity 1 national article
Ginsberg 
et al. 24
Direct medical costs: laboratory tests; prophylaxis in communicants; mild and moderate cases; 
outpatient cases with relapse; inpatient cases with relapse; severe hospital cases; non-fatal fulminant 
hepatic failure without transplan; fatal fulminant hepatic failure without transplant; non-fatal fulminant 
hepatic failure with transplant; fatal fulminant hepatic failure without transplant 
National data
Direct non-medical costs: transportation for outpatient consultations and hospitalization National data
Costs with vaccine: doses; administration; waste; adverse events; health education; transportation National statistics
Indirect costs *: lost productivity, patient; lost productivity, spouse (U.S. wage adjusted for 
unemployment rate)
2 international articles
Jacobs et al. 22 Direct medical costs: outpatient; inpatient; transplant; transplant follow-up 2 national articles; 
Transplant Registry/U.S.
Costs with vaccine: doses; administration CDC; 1 national article
Indirect costs: lost productivity in outpatients – 15 days; lost productivity in hospital patients – 
33 days (median wage, USA)
National statistics; 1 national 
article
Valenzuela 
et al. 25
Direct medical costs: outpatient; inpatient; transplant; transplant follow-up Ministry of Health of Chile
Costs with vaccine: doses; administration CDC; Ministry of Health of 
Chile
Indirect costs: lost productivity in patients 20-59 years of age – 28 days (median daily wage in Chile) Ministry of Health of Chile; 
Central Bank of Chile
Rein et al. 23 Direct medical costs: symptomatic outpatients without jaundice; unreported outpatients with 
jaundice; inpatients with jaundice; fulminant hepatic failure without transplant; transplant; transplant 
follow-up; public health costs per reported case 
3 national articles
Costs with vaccine: doses; administration CDC
Indirect costs: lost productivity for patients and caregivers (median expected weekly wage) Population survey
Armstrong 
et al. 21
Direct medical costs: public health costs ND
Costs with vaccine: dose; administration ND
Indirect costs: lost productivity following death from hepatitis A; lost productivity of patients; lost 
productivity of parents of children with hepatitis A
ND
Lopez et al. 27 Direct costs: laboratory tests; administration of immunoglobulin M; outpatient consultations; hospital 
fees; fulminant hepatic failure without transplant; fulminant hepatic failure with transplant; Re-
transplantation
National statistics; Abstract 
from Argentine study
Costs with vaccine: doses Abstract from Argentine 
study
Indirect costs ND
Ellis et al. 28 Direct medical costs: outpatient; inpatients without fulminant hepatic failure; inpatients with 
fulminant hepatic failure without transplant; inpatients with fulminant hepatic failure with transplant; 
transplant follow-up
Records and data on 
national costs
Costs with vaccine: doses; administration PAHO Revolving Fund
Indirect costs: lost productivity of patients > 17 years of age -28 days (regional wage) 3 international articles; 
National statistics
(continues)
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Table 4 (continued)
Study Cost elements Sources
Quezada et al. 26 Direct medical costs: outpatient treatment; inpatient treatment; fulminant hepatic failure with 
transplant 
3 international articles; 
2 national articles
Costs with vaccine: doses; administration; adverse events 3 international articles; 
2 national articles
Indirect costs: lost productivity of parents of patients ≤ 15 years of age – 3 days; lost productivity of 
patients > 15 years -25 days
ND
Zhuang (2008) 29 Direct medical costs: non-hospital cases; hospital cases; fatal cases Ministry of Health
Costs with vaccine: doses; administration Price paid by government; 
U.S. CDC 
Indirect costs: lost productivity of patients 18-60 years; non-hospital cases – 16 days; hospital cases – 
33 days; fatal cases – 40 days (per capita GDP/365.5)
3 international articles
CDC: Centers for Disease Control and Prevention (USA); ND: not determined; PAHO: Pan-American Health Organization; GDP: gross domestic product.
* Number of lost workdays is specifi c to types of cases: mild and moderate cases in adults (13.25 days); mild and moderate cases in children (9.29 days); 
outpatient cases with relapse (46.3 days); hospital cases with relapse (46.3 days); severe hospital cases (71 days); non-fatal fulminant hepatic failure without 
transplant (6 months for survivor and 6 weeks for spouse); fatal fulminant hepatic failure without transplant (10.5 days for deceased patient and 21 days for 
spouse); non-fatal fulminant hepatic failure with transplant (1.5 year for survivor and 1 year for spouse); fatal fulminant hepatic failure with transplant 
(10.5 days for deceased patient and 21 days for spouse).
While the United States has low endemicity, Ar-
gentina, Chile, and China are in transition from 
high to intermediate or low endemicity 14. The 
severity of hepatitis A increases with age: jaun-
dice is reported in only 7% of children less than 
four years of age with hepatitis A 30. Meanwhile, 
more than 70% of older children and adults are 
symptomatic, with clinical jaundice in 40 to 70% 
of cases 30,39. In countries with high endemicity, 
infection occurs in early childhood, and the vast 
majority of cases are asymptomatic. The tran-
sition from high to low endemicity can lead to 
an increase in age at infection, with an increase 
in symptomatic cases and thus greater utiliza-
tion of health services, which would explain the 
higher cost-effectiveness ratio in areas with ex-
tremely high endemicity.
Sensitivity analyses (Table 1) showed that 
the parameters with the greatest impact on the 
results of economic evaluations were cost of 
the vaccine dose and administration, followed 
by incidence and medical costs of the disease. 
Four 26,27,28,29 of the 10 studies presented ro-
bust results in favor of vaccination, which did 
not change with variations in the parameters for 
sensitivity analyses.
Discussion
This systematic review of economic studies on 
childhood hepatitis A vaccination showed that 
this type of study can contribute to the develop-
ment of a national decision-making model. The 
review pointed to some important issues to be 
considered when using the methodology and es-
timates of key variables in the published studies, 
especially in relation to the transferability of data 
and generalizability of results.
We observed variability among the studies 
under review in relation to the methodological 
characteristics and estimates of key variables. 
Methodological characteristics accounted for 
some differences in the studies’ results, particu-
larly the perspective and type of model used.
The type of perspective adopted by the study 
is a methodological choice. Many experts recom-
mend society’s perspective, because it is more 
comprehensive 15. In this review, when three 
studies 22,23,25 took society’s perspective, the re-
sults were very different from those obtained us-
ing the healthcare system’s perspective (Table 5). 
Although all the studies took society’s perspec-
tive (considering direct and indirect costs), in 
the Brazilian case it is also recommendable to 
conduct the study from the healthcare system’s 
perspective, because it provides results that only 
consider the amounts reimbursed by the Unified 
National Health System and can assist public 
managers in the decision making process.
As for the type of model, although most of 
the studies (7 of 10) used a Markov static model 
20,21,22,23,25,28,29, the review suggests the develop-
ment of a dynamic transmission model as the 
best option for evaluating the country’s universal 
childhood immunization program. This meth-
odological choice will require a larger amount of 
local data, for example data on hepatitis A sero-
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Table 5
Summary measures presented in results according to the perspective of the analysis and funding source.
Funding Source Perspective
Society Healthcare system
Independent
Das 20 US$ 14,948 per QALY gained ND
Ginsberg et al.24 Cost-benefit ratio *: 3.07:1 Cost-benefit ratio **: 2.17:1
Rein et al. 23 US$ 284 per averted infection
US$ 199,000 per year of life gained
US$ 28,000 per QALY gained
ND
ND
US$ 40,000 per QALY gained
Armstrong et al. 21 US$ 32,000 per QALY gained (without 
considering herd protection)
US$ 1,000 per QALY gained (considering 
herd protection)
ND
Zhuang et al. 29 < 0 ***: US$ 3,633 per year of life gained
< 0 ***: US$ 277 per QALY gained
< 0 ***: US$ 2,680 per year of life gained
< 0 ***: US$ 204 per QALY gained
Industry
Jacobs et al. 22 US$ 2,382 per year of life gained
US$ 1,516 per QALY gained
US$ 15,265 per year of life gained #
US$ 9,852 per QALY gained #
Valenzuela et al. 25 < 0 ## per year of life gained
< 0 ## per QALY gained
US$ 475-US$ 911 per year of life gained
US$ 290-US$ 520 per QALY gained
Lopez et al. 27 US$ 3,542 per year of life gained ND
Ellis et al. 28 < 0 ###: US$ 234 per QALY gained 
(1 dose of vaccine)
< 0 §: US$ 2,772 per QALY gained 
(2 doses of vaccine)
ND
Quezada et al. 26 US$ 4,984 per year of life gained ND
ND: not determined; QALY: quality-adjusted life year.
* US$ 1 invested in vaccination produces a savings of US$ 3.07;
** US$ 1 invested in vaccination produces a savings of US$ 2.17;
*** Incremental ratio was negative in regions with low, medium, intermediate, and high endemicity and was US$ 3,633 per 
year of life gained in the region 
with extremely high endemicity; incremental ratio was negative in regions with low, medium, intermediate, and high 
endemicity and was US$ 277 per QALY gained in the region with extremely high endemicity; incremental ratio was negative 
in regions with low, medium, intermediate, and high endemicity and was US$ 2,680 per year of life gained in the region with 
extremely high endemicity; incremental ratio was negative in regions with low, medium, intermediate, and high endemicity 
and was US$ 204 per QALY gained in the region with extremely high endemicity;
# Health service’s perspective;
## Negative incremental ratio means that the vaccination strategy is “cost-saving”, cost less and is more effective;
### Incremental ratio was negative in Argentina as a whole and US$ 234 per QALY gained in the Cuyo region;
§ Incremental ratio was negative in the Cuyo region and US$ 2,772 per QALY gained in the Northeast region.
prevalence in Brazil. Data from the recent Na-
tional Hepatitis Survey allow feeding a dynamic 
model for hepatitis A.
The Brazilian dynamic model should con-
sider both the positive aspects of herd protec-
tion such as the increase in averted cases of the 
disease and the negative aspects like the change 
in age at infection and proportion of symptom-
atic cases and use of health services, in order to 
avoid overestimating the beneficial effects of the 
vaccination program with more favorable cost-
effectiveness results.
Estimates of the key variables also accounted 
for differences in the results in the studies re-
viewed here.
Incidence was one of the factors with the 
greatest impact on the cost-effectiveness of uni-
versal hepatitis A vaccination programs. Cost-
effectiveness ratios in areas with low incidence 
of the infection are heavily influenced by the 
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cost of the vaccine and the inclusion of social 
costs. Cost-effectiveness in high-incidence ar-
eas proved more robust to changes in the cost 
of the vaccine or other costs 12. Data from epide-
miological estimates are considered to have low 
transferability in economic evaluations. Mea-
sures of clinical events can be misleading if there 
are differences in the underlying epidemiological 
estimates. The “guidelines” recommend the use 
of specific country data 40. In the absence of local 
data, it is recommended that data from countries 
with similar endemicity be used. Despite the ex-
istence of studies in Chile 25,26 and Argentina 27,28 
with similar epidemiological profiles, the results 
are not transferable due to the differences in the 
organization of healthcare and coverage in the 
respective health systems.
In the Brazilian case, the preference should 
be for regional analyses based on different pat-
terns of endemicity, in addition to a nationwide 
analysis. To conduct a nationwide analysis, the 
most important issue would be the availability 
of reliable data on incidence of the infection, 
number of symptomatic cases, and deaths from 
hepatitis A. The data on probability of symp-
tomatic infection (jaundice) may be transfer-
able from other studies, because in this specific 
case there is no reason for the natural history of 
the disease to differ between countries. Stud-
ies in Argentina 27,28, Chile 25,26, and China 29 
used the proportion of symptomatic individuals 
among the infected, provided by Armstrong & 
Bell 30, a study conducted in the United States. 
The Brazilian national study could repeat this 
approach. As for case-fatality, although some 
studies in the review used international data, 
the Brazilian study should use national data. 
Guidelines suggest that this estimate should 
only be transferred from similar locations in the 
absence of data on case-fatality in the country 
itself, but that the estimate should be validated 
by expert panels.
In addition, detailed data are necessary on 
access to health services, healthcare patterns, 
and use of resources in outpatient, inpatient, 
and transplant cases, as well as on post-trans-
plant follow-up. The studies reviewed here do 
not provide details on the methodology used for 
the identification and measurement of resources 
used in treatment of the previously cited cases. 
Data on use of resources are considered to have 
intermediate transferability. The guidelines from 
pharmacoeconomics recommend obtaining 
data on the use of resources from the location 
where the evaluation is being performed. Dif-
ferences in clinical practices, payment systems, 
and incentives are generally cited as the princi-
pal reasons for variation in the use of resources 
between one location and another. When there 
are no local data and it becomes necessary to 
transfer data from elsewhere, an expert panel 
is recommended for reviewing the data and 
evaluating whether the treatment patterns are 
similar, in order to produce more relevant esti-
mates for the local context 40. The Brazilian case 
requires obtaining the pattern of care practiced 
in local health services in order to determine the 
resources (medical consultations, hospitaliza-
tions, tests, drugs, etc.) and the amounts used in 
outpatient, inpatient, and transplant cases and 
post-transplant follow-up.
Most studies (8 of 10) used local data to es-
timate direct medical costs. Data from cost esti-
mates are considered to have low transferability. 
The guidelines are very strict and do not allow 
transferring these data under any circumstances. 
Cost unit estimates must be specific to the con-
text being evaluated, due to differences in ab-
solute and relative prices between countries 40. 
Thus, in the Brazilian case, direct medical costs 
for outpatient and inpatient treatment of hepati-
tis A, hepatic failure with or without subsequent 
liver transplant, and post-transplant follow-up, 
as well as the costs of the vaccine, must necessar-
ily use local data.
The inclusion of indirect costs related to lost 
productivity was important in determining the 
attractiveness of the immunization program 
(Table 5). Value assessment of lost work time de-
pends on the country’s wage and employment 
levels. Four studies 20,22,23,25 used only local data 
to estimate indirect costs, indicating greater dif-
ficulty in obtaining local data for this estimate. 
In the Brazilian national study, additional efforts 
should be made to accurately document the real 
number of lost workdays related to the disease 
locally, since indirect costs of the disease can 
have an important impact on the results of the 
analysis.
Data on the effect of treatment are consid-
ered highly transferable 40. The vaccine’s efficacy, 
obtained from randomized controlled clinical tri-
als conducted in other countries, can be used in 
the local study. The vaccination scheme should 
be adjusted to the prevailing national childhood 
immunization calendar, with two doses admin-
istered in the second year of life. Considering re-
source limitations, single-dose vaccination may 
be explored, as in the Argentine experience. Vac-
cination coverage should be estimated, based on 
the coverage of other vaccines already incorpo-
rated into the National Immunization Program 
and which are administered during the same pe-
riod (measles-mumps-rubella, administered at 
12 months, or the DTP booster, administered at 
15 months).
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Summary of Recommendations for 
a Brazilian National Model
Based on the information obtained from the ar-
ticles in this review, it is possible to summarize 
some methodological characteristics and esti-
mates of key variables to be used in the Brazilian 
national model:
• Adopt the society and healthcare system per-
spectives;
• Develop a dynamic transmission model;
• In addition to the national analysis, conduct 
regional analyses according to different patterns 
of endemicity;
• Use national data on incidence, force of in-
fection, and case-fatality;
• Use national data on access to health ser-
vices, patterns of care, and use of resources in 
outpatient, inpatient, and transplant cases;
• As a comparative strategy, adopt a vaccina-
tion scheme adjusted to the prevailing national 
childhood immunization calendar;
• Use local data to estimate direct medical 
costs;
• Use local data on coverage and cost of the 
vaccine;
• Consider international data on vaccine ef-
ficacy if local data on effectiveness are not avail-
able;
• Use local data to estimate indirect costs re-
lated to lost productivity;
• Discount costs and benefits at a 5% standard 
rate;
• Conduct sensitivity analysis for the estimates 
of incidence, cost of dose, and administration of 
the vaccine and medical costs of the disease.
Final remarks
Economic evaluations can benefit from system-
atic reviews of the clinical literature. However, 
prior review of the literature is not sufficient to 
guarantee a good economic evaluation 41. Some 
authors have questioned the contributions of 
systematic reviews and raised concerns about 
generalizing the results of economic evaluation 
studies. Unlike systematic reviews of treatment 
effects in randomized controlled clinical trials, 
the cost-effectiveness results of new interven-
tions are more context-dependent than the 
clinical efficacy results. The cost-effectiveness of 
a particular intervention is heavily influenced 
by the use of resources and the costs associated 
with the intervention, which vary between coun-
tries, regions, or types of services, as well as over 
time 42,43,44.
Economic evaluations in health make use of 
epidemiological data and data on access and use 
of health services, treatment patterns, and costs 
associated with the disease, which vary greatly 
between countries, making it very difficult to 
generalize and/or transfer the results to differ-
ent contexts. The systematic review of economic 
evaluation studies for the hepatitis A vaccine 
showed that it is not possible to generalize the 
results to the Brazilian context, and confirmed 
the need to develop a local study to estimate the 
cost-effectiveness ratio of the new vaccine to be 
incorporated.
The discussion of methodological character-
istics and estimates of key variables and the sum-
mary of recommendations provided elements 
for the development of a new decision-making 
model for Brazil.
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Resumo
O objetivo deste estudo foi apresentar as contribuições 
da revisão sistemática de avaliações econômicas pa-
ra o desenvolvimento de um estudo nacional, o caso 
da vacinação infantil contra hepatite A. Foi realiza-
da revisão da literatura nas bases de dados EMBASE, 
MEDLINE, WOPEC, HealthSTAR, SciELO e LILACS, no 
período de 1995 a 2010. A maioria dos estudos (8 em 
10) mostrou resultados favoráveis de custo-efetivida-
de. As análises de sensibilidade indicaram como parâ-
metros mais importantes para os resultados os custos 
da vacina, incidência de hepatite A e custos médicos 
da doença. Foi observada variabilidade nas caracterís-
ticas metodológicas e estimativas de variáveis-chaves 
dos 10 estudos revisados. Não é possível generalização 
dos resultados e transferibilidade de estimativas epi-
demiológicas, de usos de recursos e custos associados à 
hepatite A para o contexto local. A revisão sistemática 
dos estudos de avaliação econômica da vacina contra 
hepatite A demonstrou a necessidade de uma análise 
nacional e forneceu elementos para o desenvolvimen-
to de um novo modelo de decisão para o Brasil.
Avaliação de Custo-Efetividade; Análise Custo-Benefí-
cio; Hepatite A; Programas de Imunização
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